We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Multiplex Assay Optimized for Sexually Transmitted Bacteria

By LabMedica International staff writers
Posted on 15 Dec 2011
A relatively new isothermal nucleic acid-amplification technology has been developed to detect the most insidious of all sexually transmitted diseases of bacterial etiology.

Thermophilic helicase dependent amplification (tHDA) employs helicase to unwind double-stranded DNA at constant temperature, has now been optimized to detect Chlamydia trachomatis and Neisseria gonorrhoeae. More...


Scientists at the Research and Development department at QIAGEN Inc., (Gaithersburg, MD, USA) combined tHDA with sequence-specific sample preparation on magnetic beads and homogeneous endpoint fluorescence detection using dual-labeled probes. This four-plex tHDA assay was applied to the detection of two genes on C. trachomatis and a multicopy gene on N. gonorrhoeae in the presence of an internal control.

Gene targets for multiplex tHDA assay included C. trachomatis genomic DNA olfactory marker protein (omp) gene, C. trachomatis cryptic plasmid gene, and NG multicopy opacity protein (opa) gene. Several different strand displacement polymerases were evaluated during the tHDA assay optimization. The assay showed high analytical sensitivity and specificity of simultaneous detection of both bacteria and is compatible with a wide variety of sample types and media.

The performance of a tHDA system may be further improved as tHDA technology currently has some limitations. Nonspecific amplification and primer-dimer formation are more pronounced in tHDA than in polymerase chain reaction (PCR), making multiplexing with the tHDA system more challenging. Nonspecific amplification of tHDA products tends to occur during tHDA reaction setup at room temperature.

The isothermal reaction conditions and homogeneous endpoint detection utilized in the assay were well suited for laboratory automation and high-throughput screening applications as well as for point-of-care testing. The system is still under development but has already proved that the multiplex isothermal amplification assay with endpoint fluorescent detection is a simple and economic alternative to the real-time PCR. The study was published in the December 2011 edition of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
QIAGEN Inc.


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.